Drug Profile
TOUR 006
Alternative Names: PF-04236921; PF-4236921; TOUR-006Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Pfizer
- Developer Pfizer; Tourmaline Bio
- Class Anti-inflammatories; Antirheumatics; Cardiovascular therapies; Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Graves ophthalmopathy
- Phase I Cardiovascular disorders
- Discontinued Crohn's disease; Rheumatoid arthritis; Systemic lupus erythematosus